



# QUALITY MEASURES

## EVIDENCE-BASED CARE

### Reg-ent<sup>SM</sup> Offers a Total of 70 Quality Measures

#### Why Quality Measures are Important

Quality measures are used to monitor patient care, connect clinical outcomes with healthcare processes, and meet third-party payer requirements. AAO-HNSF is committed to providing quality measures that meet our members' requirements for public reporting to both CMS and private payers.

**AAO-HNSF Qualified Clinical Data Registry (QCDR) measures** are developed internally and only available to Reg-ent users. These are specialty-specific measures that have been approved by the Centers for Medicare & Medicaid Services for reporting in the Merit-based Incentive Payment System (MIPS).

- 18 specialty-specific AAO-HNSF developed QCDR measures

**Quality Payment Program (QPP) measures for ENT** are available publicly to any clinician reporting for MIPS and several were developed by AAO-HNSF.

- 44 public QPP measures applicable to otolaryngology-head and neck surgery

**AAO-HNSF measures for validation or gap analysis** are exclusively for Reg-ent users who express an interest in testing new measures for the specialty.

- Reg-ent also includes eight measures developed by AAO-HNSF for validation and gap analysis

## AAO-HNSF QCDR MEASURES

### OTITIS MEDIA WITH EFFUSION

- AAO 8** Otitis Media with Effusion: Antihistamines or Decongestants - Avoidance of Inappropriate Use
- AAO 11** Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids
- AAO 20** Otitis Media with Effusion: Hearing Test
- AAO 21** Audiometry for Chronic Otitis Media with Effusion in Children
- AAO 26** Otitis Media with Effusion: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility
- AAO 27** Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Children\*
- AAO 28** Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Adults\*

### CERUMEN IMPACTION

- AAO 15** Percentage of Patients with Cerumen Impaction and a Suggestive History of Non-Intact Tympanic Membrane Who Receive Just Manual Removal
- AAO 18** Percentage of Visits with Patients with Hearing Aids Where Otoscopy is Routinely Performed

### ALLERGIC RHINITIS

- AAO 22** Percentage of Patients with Allergic Rhinitis Who Do Not Receive Sinonasal Imaging for Allergic Rhinitis
- AAO 23** Percentage of Patients with Allergic Rhinitis Who Are Offered Intranasal Corticosteroids or Oral Antihistamines
- AAO 24** Percentage of Patients with Allergic Rhinitis Who Do Not Receive Leukotriene Inhibitors
- AAO 25** Percentage of Patients with Allergic Rhinitis Who Do Not Receive IgG-based Immunoglobulin Testing

### AGE-RELATED HEARING LOSS

- AAO 16** Audiometric Evaluation for Older Adults with Hearing Loss
- AAO 17** Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss - Avoidance of Inappropriate Use

### BELL'S PALSY

- AAO 13** Inappropriate Use of Magnetic Resonance Imaging or Computed Tomography Scan for Bell's Palsy (Inverse Measure)
- AAO 14** Inappropriate Use of Antiviral Monotherapy for Bell's Palsy (Inverse Measure)

### TYMPANOSTOMY TUBES

- AAO 12** Topical Ear Drop Monotherapy for Children with Acute Tympanostomy Tube Otorrhea

## QPP MEASURES FOR ENT

### ACUTE OTITIS EXTERNA

- QPP 91** Acute Otitis Externa: Topical Therapy
- QPP 93** Acute Otitis Externa: Systemic Antimicrobial Therapy

### ADULT SINUSITIS

- QPP 331** Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)
- QPP 332** Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Acute Bacterial Sinusitis (Appropriate Use)
- QPP 333** Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)
- QPP 334** Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)

### ASTHMA

- QPP 398** Optimal Asthma Control\*+
- QPP 444** Medication Management for People with Asthma+

### FALLS

- QPP 154** Falls: Risk Assessment+
- QPP 155** Falls: Plan of Care+

### OTITIS MEDIA WITH EFFUSION

- QPP 464** Otitis Media with Effusion: Systemic Antimicrobials+

### SLEEP APNEA

- QPP 276** Sleep Apnea: Assessment of Sleep Symptoms
- QPP 277** Sleep Apnea: Severity Assessment at Initial Diagnosis
- QPP 278** Sleep Apnea: Positive Airway Pressure Therapy Prescribed
- QPP 279** Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy

## MEASURES FOR VALIDATION/GAP ANALYSIS ONLY

### AGE-RELATED HEARING LOSS

- Screening for Hearing Loss in Older Adults
- Shared Decision Making for Treatment Options for Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss

### CERUMEN MANAGEMENT

- Percentage of Patients with Cerumen Impaction Who Receive Treatment with At Least One Appropriate Intervention

### HOARSENESS

- Postoperative Laryngeal Examination for Dysphonia

### TONSILLECTOMY

- Tonsillectomy: Primary Post-Tonsillectomy Hemorrhage in Children
- Tonsillectomy: Primary Post-Tonsillectomy Hemorrhage in Adults
- Tonsillectomy: Secondary Post-Tonsillectomy Hemorrhage in Children
- Tonsillectomy: Secondary Post-Tonsillectomy Hemorrhage in Adults

\* Denotes an outcome measure + Denotes high priority measure

## GENERAL QPP MEASURES

### MEDICATION

- QPP 46** Medication Reconciliation Post-Discharge+
- QPP 130** Documentation of Current Medications in the Medical Record+
- QPP 238** Use of High-Risk Medications in the Elderly+

### OPIOID THERAPY

- QPP 408** Opioid Therapy Follow-up Evaluation
- QPP 412** Documentation of Signed Opioid Treatment Agreement
- QPP 414** Evaluation or Interview for Risk of Opioid Misuse

### PERIOPERATIVE CARE

- QPP 21** Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
- QPP 23** Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)+

### PREVENTIVE CARE & SCREENING

- QPP 110** Preventive Care and Screening: Influenza Immunization
- QPP 111** Pneumococcal Vaccination Status for Older Adults
- QPP 128** Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
- QPP 226** Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- QPP 317** Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
- QPP 402** Tobacco Use and Help with Quitting Among Adolescents
- QPP 431** Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling

### RESPIRATORY DISEASES

- QPP 65** Appropriate Treatment for Children with Upper Respiratory Infection (URI)
- QPP 66** Appropriate Testing for Children with Pharyngitis
- QPP 116** Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

### SURGERY

- QPP 355** Unplanned Reoperation within the 30-Day Postoperative Period\*+
- QPP 356** Unplanned Hospital Readmission within 30 Days of Principal Procedure\*+
- QPP 357** Surgical Site Infection (SSI)\*+
- QPP 358** Patient-Centered Surgical Risk Assessment and Communication+

### OTHER

- QPP 47** Care Plan+
- QPP 131** Pain Assessment and Follow-Up+
- QPP 261** Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness+
- QPP 265** Biopsy Follow-Up+
- QPP 374** Closing the Referral Loop: Receipt of Specialist Report+
- QPP 404** Anesthesiology Smoking Abstinence+
- QPP 435** Quality of Life Assessment For Patients With Primary Headache Disorders\*+

\* Denotes an outcome measure + Denotes high priority measure

To learn more about Reg-ent and the MIPS 2018 quality measures, visit [www.reg-ent.org](http://www.reg-ent.org) or email [reg-ent@entnet.org](mailto:reg-ent@entnet.org).

If you have any quality or measures specific questions please contact us at [measures@entnet.org](mailto:measures@entnet.org).